Redeye: Orphazyme - Detailed data shines more light on NPC project

Additional details from the 12-month NPC trial gives a better understanding of arimoclomol in NPC, but there's still uncertainty around the path forward.

Read more and download the initial research report: http://bit.ly/2UuLwsx

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/